Flower lose, a cell fitness marker, predicts COVID-19 prognosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Flower lose, a cell fitness marker, predicts COVID-19 prognosis. / Yekelchyk, Michail; Madan, Esha; Wilhelm, Jochen; Short, Kirsty R.; Palma, António M.; Liao, Linbu; Camacho, Denise; Nkadori, Everlyne; Winters, Michael T.; Rice, Emily S.; Rolim, Inês; Cruz-Duarte, Raquel; Pelham, Christopher J.; Nagane, Masaki; Gupta, Kartik; Chaudhary, Sahil; Braun, Thomas; Pillappa, Raghavendra; Parker, Mark S.; Menter, Thomas; Matter, Matthias; Haslbauer, Jasmin Dionne; Tolnay, Markus; Galior, Kornelia D.; Matkwoskyj, Kristina A.; McGregor, Stephanie M.; Muller, Laura K.; Rakha, Emad A.; Lopez-Beltran, Antonio; Drapkin, Ronny; Ackermann, Maximilian; Fisher, Paul B.; Grossman, Steven R.; Godwin, Andrew K.; Kulasinghe, Arutha; Martinez, Ivan; Marsh, Clay B.; Tang, Benjamin; Wicha, Max S.; Won, Kyoung Jae; Tzankov, Alexandar; Moreno, Eduardo; Gogna, Rajan.

I: EMBO Molecular Medicine, Bind 13, Nr. 11, e13714, 2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Yekelchyk, M, Madan, E, Wilhelm, J, Short, KR, Palma, AM, Liao, L, Camacho, D, Nkadori, E, Winters, MT, Rice, ES, Rolim, I, Cruz-Duarte, R, Pelham, CJ, Nagane, M, Gupta, K, Chaudhary, S, Braun, T, Pillappa, R, Parker, MS, Menter, T, Matter, M, Haslbauer, JD, Tolnay, M, Galior, KD, Matkwoskyj, KA, McGregor, SM, Muller, LK, Rakha, EA, Lopez-Beltran, A, Drapkin, R, Ackermann, M, Fisher, PB, Grossman, SR, Godwin, AK, Kulasinghe, A, Martinez, I, Marsh, CB, Tang, B, Wicha, MS, Won, KJ, Tzankov, A, Moreno, E & Gogna, R 2021, 'Flower lose, a cell fitness marker, predicts COVID-19 prognosis', EMBO Molecular Medicine, bind 13, nr. 11, e13714. https://doi.org/10.15252/emmm.202013714

APA

Yekelchyk, M., Madan, E., Wilhelm, J., Short, K. R., Palma, A. M., Liao, L., Camacho, D., Nkadori, E., Winters, M. T., Rice, E. S., Rolim, I., Cruz-Duarte, R., Pelham, C. J., Nagane, M., Gupta, K., Chaudhary, S., Braun, T., Pillappa, R., Parker, M. S., ... Gogna, R. (2021). Flower lose, a cell fitness marker, predicts COVID-19 prognosis. EMBO Molecular Medicine, 13(11), [e13714]. https://doi.org/10.15252/emmm.202013714

Vancouver

Yekelchyk M, Madan E, Wilhelm J, Short KR, Palma AM, Liao L o.a. Flower lose, a cell fitness marker, predicts COVID-19 prognosis. EMBO Molecular Medicine. 2021;13(11). e13714. https://doi.org/10.15252/emmm.202013714

Author

Yekelchyk, Michail ; Madan, Esha ; Wilhelm, Jochen ; Short, Kirsty R. ; Palma, António M. ; Liao, Linbu ; Camacho, Denise ; Nkadori, Everlyne ; Winters, Michael T. ; Rice, Emily S. ; Rolim, Inês ; Cruz-Duarte, Raquel ; Pelham, Christopher J. ; Nagane, Masaki ; Gupta, Kartik ; Chaudhary, Sahil ; Braun, Thomas ; Pillappa, Raghavendra ; Parker, Mark S. ; Menter, Thomas ; Matter, Matthias ; Haslbauer, Jasmin Dionne ; Tolnay, Markus ; Galior, Kornelia D. ; Matkwoskyj, Kristina A. ; McGregor, Stephanie M. ; Muller, Laura K. ; Rakha, Emad A. ; Lopez-Beltran, Antonio ; Drapkin, Ronny ; Ackermann, Maximilian ; Fisher, Paul B. ; Grossman, Steven R. ; Godwin, Andrew K. ; Kulasinghe, Arutha ; Martinez, Ivan ; Marsh, Clay B. ; Tang, Benjamin ; Wicha, Max S. ; Won, Kyoung Jae ; Tzankov, Alexandar ; Moreno, Eduardo ; Gogna, Rajan. / Flower lose, a cell fitness marker, predicts COVID-19 prognosis. I: EMBO Molecular Medicine. 2021 ; Bind 13, Nr. 11.

Bibtex

@article{bf07c2022a2945858d2f51ad1bf2e6c5,

title = "Flower lose, a cell fitness marker, predicts COVID-19 prognosis",

abstract = "Risk stratification of COVID-19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe-Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe-Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID-19 patients. We performed a post-mortem examination of infected lung tissue in deceased COVID-19 patients to determine hFwe-Lose{\textquoteright}s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe-Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID-19 patients. In COVID-19 patients with acute lung injury, hFwe-Lose is highly expressed in the lower respiratory tract and is co-localized to areas of cell death. In patients presenting in the early phase of COVID-19 illness, hFwe-Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe-Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D-dimer, C-reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe-Lose, accurately predicts outcomes in COVID-19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID-19 pandemic.",

keywords = "biomarker, cell fitness, COVID-19, flower, prognosis",

author = "Michail Yekelchyk and Esha Madan and Jochen Wilhelm and Short, {Kirsty R.} and Palma, {Ant{\'o}nio M.} and Linbu Liao and Denise Camacho and Everlyne Nkadori and Winters, {Michael T.} and Rice, {Emily S.} and In{\^e}s Rolim and Raquel Cruz-Duarte and Pelham, {Christopher J.} and Masaki Nagane and Kartik Gupta and Sahil Chaudhary and Thomas Braun and Raghavendra Pillappa and Parker, {Mark S.} and Thomas Menter and Matthias Matter and Haslbauer, {Jasmin Dionne} and Markus Tolnay and Galior, {Kornelia D.} and Matkwoskyj, {Kristina A.} and McGregor, {Stephanie M.} and Muller, {Laura K.} and Rakha, {Emad A.} and Antonio Lopez-Beltran and Ronny Drapkin and Maximilian Ackermann and Fisher, {Paul B.} and Grossman, {Steven R.} and Godwin, {Andrew K.} and Arutha Kulasinghe and Ivan Martinez and Marsh, {Clay B.} and Benjamin Tang and Wicha, {Max S.} and Won, {Kyoung Jae} and Alexandar Tzankov and Eduardo Moreno and Rajan Gogna",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Published under the terms of the CC BY 4.0 license",

year = "2021",

doi = "10.15252/emmm.202013714",

language = "English",

volume = "13",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

number = "11",

}

RIS

TY - JOUR

T1 - Flower lose, a cell fitness marker, predicts COVID-19 prognosis

AU - Yekelchyk, Michail

AU - Madan, Esha

AU - Wilhelm, Jochen

AU - Short, Kirsty R.

AU - Palma, António M.

AU - Liao, Linbu

AU - Camacho, Denise

AU - Nkadori, Everlyne

AU - Winters, Michael T.

AU - Rice, Emily S.

AU - Rolim, Inês

AU - Cruz-Duarte, Raquel

AU - Pelham, Christopher J.

AU - Nagane, Masaki

AU - Gupta, Kartik

AU - Chaudhary, Sahil

AU - Braun, Thomas

AU - Pillappa, Raghavendra

AU - Parker, Mark S.

AU - Menter, Thomas

AU - Matter, Matthias

AU - Haslbauer, Jasmin Dionne

AU - Tolnay, Markus

AU - Galior, Kornelia D.

AU - Matkwoskyj, Kristina A.

AU - McGregor, Stephanie M.

AU - Muller, Laura K.

AU - Rakha, Emad A.

AU - Lopez-Beltran, Antonio

AU - Drapkin, Ronny

AU - Ackermann, Maximilian

AU - Fisher, Paul B.

AU - Grossman, Steven R.

AU - Godwin, Andrew K.

AU - Kulasinghe, Arutha

AU - Martinez, Ivan

AU - Marsh, Clay B.

AU - Tang, Benjamin

AU - Wicha, Max S.

AU - Won, Kyoung Jae

AU - Tzankov, Alexandar

AU - Moreno, Eduardo

AU - Gogna, Rajan

PY - 2021

Y1 - 2021

N2 - Risk stratification of COVID-19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe-Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe-Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID-19 patients. We performed a post-mortem examination of infected lung tissue in deceased COVID-19 patients to determine hFwe-Lose’s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe-Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID-19 patients. In COVID-19 patients with acute lung injury, hFwe-Lose is highly expressed in the lower respiratory tract and is co-localized to areas of cell death. In patients presenting in the early phase of COVID-19 illness, hFwe-Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe-Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D-dimer, C-reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe-Lose, accurately predicts outcomes in COVID-19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID-19 pandemic.

AB - Risk stratification of COVID-19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe-Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe-Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID-19 patients. We performed a post-mortem examination of infected lung tissue in deceased COVID-19 patients to determine hFwe-Lose’s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe-Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID-19 patients. In COVID-19 patients with acute lung injury, hFwe-Lose is highly expressed in the lower respiratory tract and is co-localized to areas of cell death. In patients presenting in the early phase of COVID-19 illness, hFwe-Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe-Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D-dimer, C-reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe-Lose, accurately predicts outcomes in COVID-19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID-19 pandemic.

KW - biomarker

KW - cell fitness

KW - COVID-19

KW - flower

KW - prognosis

U2 - 10.15252/emmm.202013714

DO - 10.15252/emmm.202013714

M3 - Journal article

C2 - 34661368

AN - SCOPUS:85117102080

VL - 13

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 11

M1 - e13714

ER -

ID: 282471969